| Literature DB >> 25279189 |
Rena Yuasa1, Yoshinobu Hata1, Hajime Otsuka1, Takashi Makino1, Satoshi Koezuka1, Fumitomo Sato1, Kazuyoshi Tamaki1, Shuichi Sasamoto1, Keigo Takagi2, Akira Iyoda1.
Abstract
The indications and suitable approaches for treating upper airway obstruction secondary to thyroid cancer are controversial. Patients with thyroid cancer generally have a good prognosis, but airway stenosis and vocal cord paralysis are not uncommon. Subglottic airway stenting may be challenging, due to stent migration, granulation tissue formation and supraglottic stenosis. In this study, we evaluated the application of covered self-expandable metallic stents to relieve upper airway obstruction. This was a retrospective study of 5 patients with airway stenosis due to thyroid cancer treated in 2009 and 2010. Immediate airway enlargement was achieved in 3 patients with stenosis at the middle mediastinum. Gradual enlargement over 2 months was observed in the remaining 2 patients with stenosis at the cervical level. The performance status was improved in all 5 patients, including a case with anaplastic carcinoma. The follow-up averaged 13 months (range, 8-27 months). Granulation tissue developed at both ends of the stent in 3 patients, sputum was retained in 2 cases and bacterial colonization was detected in all 5 cases. No stent migration was reported. Additional tracheostomy was required in 2 patients, due to proximal tumor growth or progressive bilateral vocal cord paralysis after 10 and 6 months, respectively. In conclusion, stenting for central airway stenosis secondary to thyroid cancer may be beneficial, even in patients with anaplastic carcinoma. Long-term regular bronchoscopic follow-up is required to monitor complications, as patients with thyroid cancer are at high risk of granulation tissue formation, sputum retention and bacterial colonization.Entities:
Keywords: airway obstruction; flexible bronchoscopy; self-expandable metallic stents; thyroid cancer; tracheal stenosis
Year: 2014 PMID: 25279189 PMCID: PMC4179784 DOI: 10.3892/mco.2014.350
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450